Organoprotection in patients with COVID-19

  • V.K. Tashchuk Bukovinian State Medical University, Chernivtsi, Ukraine


Background. Treatment of chronic coronary syndrome (CCS) includes the elimination of acute ischemic pain, prevention of ischemic pain, symptomatic treatment, and influence on the prognosis. The health of patients with CCS during their lifetime is affected by the diet, climate, medication, exposure to toxic substances, and now the COVID-19 epidemic.

Objective. To describe the available options of cardioprotection and metabolic therapy.

Materials and methods. Analysis of literature data on this topic and own research “Smart ECG”.

Results and discussion. A significant number of the foreign scientists’ papers have been devoted to the problems of the excessive release of free radicals, mitochondrial DNA damage, reduction of ATP content and cardiocytoprotection. Even the short-term ischemia depletes ATP depots and slows their recovery. Metabolic therapy is able to protect cardiomyocytes from the hypoxic death due to the mismatch of energy production by mitochondria to the energy needs of the cell. According to the results of the own study “Smart ECG”, L-arginine and L-carnitine (Tivorel, “Yuria-Pharm”) activates parasympathetic regulation in stable angina, reducing the risk of adverse events. Vascular, immunomodulatory, antioxidant and cytoprotective properties of L-carnitine and L-arginine make their use reasonable for COVID-19.

Conclusions. 1. Metabolic therapy is an important component of the treatment of CCS. 2. L-carnitine and L-arginine have the pronounced vascular, immunomodulatory, antioxidant and cytoprotective properties. 3. It is reasonable to use these drugs during an epidemic of COVID-19.

Keywords: metabolic therapy, chronic coronary syndrome, L-arginine, L-carnitine.
How to Cite
Tashchuk , V. (2020). Organoprotection in patients with COVID-19. Infusion & Chemotherapy, (3.2), 274-275.
Oral presentation materials of IV International Congress of infusion therapy